Ra Pharmaceuticals — Technical Presentation (December 2016)
6 slides from Ra Pharmaceuticals's technical presentation, Dec 2, 2016
Slide 1: Introducing RA101495: A Novel Subcutaneously-Administered Peptide Inhibitor of C5 for PNH
Introducing RA101495: A Novel Subcutaneously-Administered Peptide Inhibitor of C5 for PNH Blocks C5 cleavage and production of C5a and C5b Phase 1 data in healthy volunteers shows rapid, complete, and sustained inhibition of ex vivo hemolysis Distinct from eculizumab binding site allows treatment of
Slide 2: 0.3 mg/kg Load + 0.1 mg/kg q.d.: Predicted to Achieve Rapid, Complete, and Sustained Inhibition of Hemolysis
0.3 mg/kg Load + 0.1 mg/kg q.d.: Predicted to Achieve Rapid, Complete, and Sustained Inhibition of Hemolysis 0.3 mg/kg Loading + 0.1 mg/kg q.d. 5
Slide 3: 0.1 mg/kg q.d.: Expected to Maintain Inhibition of Hemolysis at all Times in all Patients
0.1 mg/kg q.d.: Expected to Maintain Inhibition of Hemolysis at all Times in all Patients 0.1 mg/kg 6
Slide 4: RA101495 Protects Against Complement-Mediated Hemolysis of Type III PNH Erythrocytes
RA101495 Protects Against Complement-Mediated Hemolysis of Type III PNH Erythrocytes Dose response Drug concentration No drug Approx. 1 μM RA101495 RA101495 or Ecu (Note: bivalent) No drug Eculizumab Flow cytometry Serum + HCl Serum + HCl + Serum + HCl + Eculizumab (1 μM) Serum* RA101495 (1.2 μM) Ty
Slide 5: Discovery of Oral Small Molecules Protecting Against Complement-Mediated Hemolysis of Type III PNH Erythrocytes
Discovery of Oral Small Molecules Protecting Against Complement-Mediated Hemolysis of Type III PNH Erythrocytes Series of orally bioavailable (%F>30) small molecules that bind C5, inhibit its cleavage/activation (IC50 14 nM in high sensitivity sheep RBC lysis assay), and prevent hemolysis of PNH ery
Slide 6: Discovery of Oral Small Molecules Protecting Against Complement-Mediated Hemolysis of Type III PNH Erythrocytes
aeereetery Mediated rr of Type Ill PNH Erythrocytes \Ra/Pharma > Series of orally bioavailable (%F>30) small molecules that bind C5, inhibit its cleavage/activation (ICsy 14 nM in high sensitivity sheep RBC lysis assay), and prevent hemolysis of PNH erythrocytes in a dose dependent manner Serum + HC
Ra Pharmaceuticals — Technical Presentation (December 2016) on 6ix